Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
The U.S. Food and Drug Administration (FDA) is notifying the public that information on the
cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to
the physician labeling and patient Medication Guide. This information was first announced by FDA on
September 23, 2010 as part of new restrictions for prescribing and use of this drug.
Rosiglitazone is sold as a single-ingredient product under the brand name Avandia. Rosiglitazone is
also sold as a combination product under the brand name Avandamet (contains rosiglitazone and
metformin) and under the brand name Avandaryl (contains rosiglitazone and glimepiride).
In addition to describing the cardiovascular risks, the drug labels have been revised to state
that rosiglitazone and rosiglitazone-containing medicines should only be used:
patients already being treated with these medicines
- In patients whose blood sugar cannot
be controlled with other anti-diabetic medicines and who, after consulting with their healthcare
professional, do not wish to use pioglitazone-containing medicines (Actos, Actoplus Met, Actoplus
Met XR, or Duetact).
For more information, please visit: Avandia Labeling Update